Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
Status:
NOT_YET_RECRUITING
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of Becotatug Vedotin as an adjuvant therapy in patients with high-risk locoregionally advanced nasopharyngeal carcinoma (NPC).
Phase:
PHASE2
Details
Lead Sponsor:
Kai Hu
Collaborators:
Affiliated Hospital of Youjiang Medical University for Nationalitie Afliated Hospital of North Sichuan Medical College First People's Hospital of Yulin Guigang People's Hospital Hainan Cancer Hospital Lingshan people's Hospital LiuZhou People's Hospital People's Hospital of Guangxi Zhuang Autonomous Region The Third people's hospital of Hechi Wuzhou Red Cross Hospital